Dendritic cell (DC)-based
cancer vaccines, where the patient's own immune system is harnessed to target and destroy
tumor tissue, have emerged as a potent therapeutic strategy. In the development of such DC
vaccines, it is crucial to load the DCs with
tumor antigens, and to simultaneously activate them to become more potent antigen-presenting cells. For this, we report on
microbubbles, loaded with both
antigen mRNA as well as immunomodulating
TriMix mRNA, which can be used for the ultrasound-triggered transfection of DCs. In vivo experiments with in vitro sonoporated DCs show the effective induction of
antigen-specific T cells, resulting in specific lysis of
antigen-expressing cells. Especially in a therapeutic setting, sonoporation with
TriMix has an important added value, resulting in a significant reduction of
tumor outgrowth and a marked increase in overall survival. What is more, complete
tumor regression was observed in 30% of the antigen+TriMix DC vaccinated animals, which also displayed long-term
antigen-specific immunological memory. As a result, DC sonoporation using
microbubbles loaded with a combination of
antigen and
TriMix mRNA can elicit powerful immune responses in vivo, and might serve as a potential tool for further in vivo DC vaccination applications.